|Bid||6.20 x 4000|
|Ask||6.44 x 1800|
|Day's Range||6.02 - 6.32|
|52 Week Range||2.71 - 10.89|
|Beta (5Y Monthly)||1.56|
|PE Ratio (TTM)||7.83|
|Earnings Date||May 05, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.70|
Endo International plc (NASDAQ: ENDP) and ADVANZ PHARMA Corp. Limited, a specialty pharmaceutical company with a strategic focus on complex medicines, are pleased to announce today that Endo International plc's subsidiary Endo Ventures Limited has entered into a definitive agreement with Correvio International Sàrl entity, a subsidiary of ADVANZ PHARMA, to commercialize and distribute on an exclusive basis Xydalba® (dalbavancin hydrochloride) in Canada.
Endo International plc (NASDAQ: ENDP) today announced the entry of an order granting a default judgment on liability against its wholly-owned subsidiaries Endo Health Solutions Inc. (EHSI) and Endo Pharmaceuticals Inc. (EPI) in Staubus, et al. v. Purdue Pharma, L.P., et al., Case No. C-41916, which has been pending in the Circuit Court for Sullivan County at Kingsport, Tennessee since 2017.
OTTAWA, ON, March 28, 2021 /CNW/ -Note: All times localOttawa, Ontario Private meetings.The Prime Minister will participate in a United Nations Meeting of Heads of State and Government on the International Debt Architecture and Liquidity.